1
|
Calmettes V, Badrignans M, Konstantinou MP, Tancrède-Bohin E, Vignon-Pennamen MD, Castel M, Pham-Ledard A, Le Roux-Villet C, Misery L, Schoenlaub P, Tronquoy AF, Cordel N, Ortonne N, Sohier P, Cellier L, Tournier E, De La Salle EM, Le Flahec G, Plantier F, Grootenboer-Mignot S, Jouen F, Hillion B, Aractingi S, Duvert-Lehembre S, Dupin N, Ingen-Housz-Oro S. IgA and IgG/IgA intercellular dermatosis: a clinicopathological case series of 15 patients. J Eur Acad Dermatol Venereol 2022; 36:e896-e898. [PMID: 35694900 DOI: 10.1111/jdv.18325] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2022] [Accepted: 06/03/2022] [Indexed: 12/16/2022]
Affiliation(s)
- V Calmettes
- Department of Dermatology, Henri Mondor University Hospital, AP-HP, Créteil, France
| | - M Badrignans
- Department of Pathology, Henri Mondor University Hospital, AP-HP, Créteil, France
| | - M P Konstantinou
- Department of Dermatology, University Hospital of Toulouse, Toulouse, France
| | - E Tancrède-Bohin
- Department of Dermatology, Saint Louis University Hospital, APHP, Paris, France
| | - M D Vignon-Pennamen
- Department of Pathology, Saint Louis University Hospital, APHP, Paris, France
| | - M Castel
- Department of Dermatology, University Hospital of Rouen, Rouen, France
| | - A Pham-Ledard
- Department of Dermatology, CHU Bordeaux and INSERM U1312, Bordeaux, France
| | - C Le Roux-Villet
- Department of Dermatology, University Hospital Avicenne, Bobigny, France
| | - L Misery
- Department of Dermatology, University Hospital of Brest, Brest, France
| | - P Schoenlaub
- Department of Dermatology, Hopital d'Instruction des Armées, Brest, France
| | - A F Tronquoy
- Department of Dermatology, Hospital of Boulogne-sur-Mer, Boulogne-sur-Mer, France
| | - N Cordel
- Department of Dermatology and Clinical Immunology, Guadeloupe University Hospital, Pointe-à-Pitre, France
| | - N Ortonne
- Department of Pathology, Henri Mondor University Hospital, AP-HP, Créteil, France
| | - P Sohier
- Department of Pathology, Cochin Hospital, AP-HP, AP-HP, Centre-Université de Paris, Paris, France
| | - L Cellier
- Department of Pathology, University Hospital of Rouen, Rouen, France
| | - E Tournier
- Derpartment of Pathology, University Hospital of Toulouse, Toulouse, France
| | - E M De La Salle
- Department of Pathology, University Hospital of Lille, Lille, France
| | - G Le Flahec
- Department of Pathology, University Hospital of Brest, Brest, France
| | - F Plantier
- Cabinet de Pathologie Mathurin Moreau, Paris, France
| | | | - F Jouen
- Department of Immunology, University Hospital of Rouen, Rouen, France
| | - B Hillion
- Department of Dermatology, Hospital of Marne la Vallée, Jossigny, France
| | - S Aractingi
- Department of Dermatology, Cochin Hospital, AP-HP, AP-HP, Centre-Université de Paris, Paris, France
| | - S Duvert-Lehembre
- Department of Dermatology, Hospital of Dunkerque, Dunkerque, France.,Department of Dermatology, University Hospital of Lille, Lille, France
| | - N Dupin
- Department of Dermatology, Cochin Hospital, AP-HP, AP-HP, Centre-Université de Paris, Paris, France
| | - S Ingen-Housz-Oro
- Department of Dermatology, Henri Mondor University Hospital, AP-HP, Créteil, France.,Univ Paris Est Créteil EpidermE, Créteil, France
| | -
- French Bullous Diseases Study Group Paris, Paris, France
| |
Collapse
|
2
|
Weill A, Descamps V, Chasset F, Mahévas T, Bourgault-Villada I, Wolkenstein P, Chollet-Martin S, Ingen-Housz-Oro S, Grootenboer-Mignot S. Erythema multiforme associated with anti-plakin antibodies: a multicentric retrospective case series. J Eur Acad Dermatol Venereol 2022; 36:2438-2442. [PMID: 35607912 DOI: 10.1111/jdv.18259] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2021] [Accepted: 05/05/2022] [Indexed: 11/28/2022]
Abstract
BACKGROUND Erythema multiforme (EM) is a muco-cutaneous inflammatory disease mainly triggered by herpes simplex virus (HSV) recurrences. Association of EM and circulating auto-antibodies against plakins (anti-PLK-Abs [EM-PLK+]) has been reported. However, little is known about this subset of EM. OBJECTIVES We aimed to describe the clinical and immunological features and response to treatment of EM-PLK+. METHODS We conducted a retrospective multicentric study of EM-PLK+ selected from the database of the immunological laboratory of Bichat hospital, Paris, France, from January 2009 to December 2020. Anti-PLK-Abs were detected in ≥1 immunological tests: immunofluorescence assay, immunoblotting and/or ELISA. Patients with alternative diagnoses were excluded. RESULTS We included 29 patients (16 women, median age 25 [range 2-58] years). EM-PLK+ were mostly major (EM with ≥2 mucosal involvements; n = 24, 83%) and relapsing (≥2 flares; n = 23, 79%). Cutaneous lesions were target (n = 13, 54%) and target-like lesions (n = 9, 38%) with usual topography (acral, n = 19, 79%; limbs, n = 21, 88%). Mucosal lesions affected the mouth (n = 27, 96%) and genitalia (n = 19, 68%), with a median of 2 [range 0-5] mucous membranes. EM-PLK+ were suspected as certain or possible postherpetic (EM-HSV) in 19 cases (65.5%); no triggering factors were detected in 9 (31%) patients. Desmoplakin-I/II Abs were the most frequent anti-PLK-Abs (n = 20, 69%); envoplakin and periplakin Abs were detected in 11 and 9 cases. Relapsing EM-PLK+ (n = 23) were still active (≥1 flare within 6 months) in 13 (57%) patients despite immunosuppressive therapy (n = 8, 62%). Antiviral drugs were ineffective in preventing relapse in 15/16 (94%) EM-HSV. CONCLUSION The rationale for anti-PLK-Ab detection in EM is not elucidated. More systematic research of anti-PLK-Abs is warranted to better understand whether this association reflects humoral immune activity in a subset of EM or is fortuitous, related to an epitope spreading process. However, EM-PLK+ seems to be associated with major and relapsing subtypes, and difficult-to-treat cases.
Collapse
Affiliation(s)
- A Weill
- Department of Dermatology, CHU Henri Mondor, AP-HP, Créteil, France.,Referral Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France.,Referral Center for Auto-Immune Bullous Diseases (MALIBUL), AP-HP, Paris, France
| | - V Descamps
- Department of Dermatology, CHU Bichat, AP-HP, Paris, France
| | - F Chasset
- Faculty of Medicine, Department of Dermatology, CHU Tenon, AP-HP, Sorbonne Université, Paris, France
| | - T Mahévas
- Department of Dermatology, CHU Saint-Louis, AP-HP, Paris, France
| | - I Bourgault-Villada
- Department of Dermatology, CHU Ambroise Paré, AP-HP, Boulogne Billancourt, France
| | - P Wolkenstein
- Department of Dermatology, CHU Henri Mondor, AP-HP, Créteil, France.,Referral Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France.,Referral Center for Auto-Immune Bullous Diseases (MALIBUL), AP-HP, Paris, France.,Univ Paris Est Créteil Epiderm E, Créteil, France
| | | | - S Ingen-Housz-Oro
- Department of Dermatology, CHU Henri Mondor, AP-HP, Créteil, France.,Referral Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France.,Referral Center for Auto-Immune Bullous Diseases (MALIBUL), AP-HP, Paris, France.,Univ Paris Est Créteil Epiderm E, Créteil, France
| | - S Grootenboer-Mignot
- Referral Center for Auto-Immune Bullous Diseases (MALIBUL), AP-HP, Paris, France.,Department of Immunobiology, CHU Bichat, AP-HP, Paris, France
| |
Collapse
|
3
|
Common M, El Khalifa J, Beytout Q, Grootenboer-Mignot S, Deschamps L, Descamps V. Non-coeliac gluten sensitivity: an underdiagnosed condition in dermatology? J Eur Acad Dermatol Venereol 2021; 36:e102-e104. [PMID: 34487592 DOI: 10.1111/jdv.17642] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2021] [Accepted: 09/02/2021] [Indexed: 11/26/2022]
Affiliation(s)
- M Common
- Dermatology Department, Bichat Claude Bernard University Hospital, Paris, France
| | - J El Khalifa
- Dermatology Department, Bichat Claude Bernard University Hospital, Paris, France
| | - Q Beytout
- Anatomopathology Department, Bichat Claude Bernard University Hospital, Paris, France
| | | | - L Deschamps
- Anatomopathology Department, Bichat Claude Bernard University Hospital, Paris, France
| | - V Descamps
- Dermatology Department, Bichat Claude Bernard University Hospital, Paris, France
| |
Collapse
|
4
|
Haddad N, Bourrat E, Caux F, Grootenboer-Mignot S, Alexandre M, Prost C. Pemphigoïde des muqueuses à laminine 332 dans une fratrie atteinte d’épidermolyse bulleuse jonctionnelle non Herlitz, avec mutations à l’état hétérozygote composite du gène codant la chaine β3 de la laminine 332. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.094] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
5
|
Giraud L, Welfringer-Morin A, Boccara O, Frassati-Biaggi A, Leclerc-Mercier S, Grootenboer-Mignot S, Bodemer C, Hadj-Rabia S. Neonatal and self-healing linear immunoglobulin A dermatosis. J Eur Acad Dermatol Venereol 2019; 34:e86-e87. [PMID: 31574167 DOI: 10.1111/jdv.15989] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- L Giraud
- Dermatology and Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC), Université de Paris Centre, Institut Imagine, Hôpital Universitaire Necker-Enfants Malades, APHP, Paris, France
| | - A Welfringer-Morin
- Dermatology and Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC), Université de Paris Centre, Institut Imagine, Hôpital Universitaire Necker-Enfants Malades, APHP, Paris, France
| | - O Boccara
- Dermatology and Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC), Université de Paris Centre, Institut Imagine, Hôpital Universitaire Necker-Enfants Malades, APHP, Paris, France
| | - A Frassati-Biaggi
- Department of Pathology, Necker-Enfants Malades Hospital, APHP, Paris, France
| | - S Leclerc-Mercier
- Department of Pathology, Necker-Enfants Malades Hospital, APHP, Paris, France
| | - S Grootenboer-Mignot
- Department of Immunology, APHP, Bichat Hospital, Inserm UMR 1152, Université Paris Diderot Paris 7, Paris, France
| | - C Bodemer
- Dermatology and Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC), Université de Paris Centre, Institut Imagine, Hôpital Universitaire Necker-Enfants Malades, APHP, Paris, France
| | - S Hadj-Rabia
- Dermatology and Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC), Université de Paris Centre, Institut Imagine, Hôpital Universitaire Necker-Enfants Malades, APHP, Paris, France
| |
Collapse
|
6
|
Viarnaud A, Ingen-Housz-Oro S, Marque M, Valeyrie-Allanore L, Ortonne N, Gueudry J, Grootenboer-Mignot S, Muraine M, Bequignon E, Gagnière C, Schlemmer F, Wolkenstein P, Chosidow O. Severe sequelae of erythema multiforme: three cases. J Eur Acad Dermatol Venereol 2017; 32:e34-e36. [DOI: 10.1111/jdv.14478] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Affiliation(s)
- A. Viarnaud
- Dermatology; AP-HP, Henri Mondor hospital; Créteil France
| | - S. Ingen-Housz-Oro
- Dermatology; AP-HP, Henri Mondor hospital; Créteil France
- EA 7379 EpiDermE (Epidemiologie en Dermatologie et Evaluation des Thérapeutiques); Université Paris-Est Creteil Val de Marne (UPEC); Creteil France
- Referral center for toxic bullous diseases; Créteil France
| | - M. Marque
- Dermatology; Caremeau hospital; Nîmes France
| | - L. Valeyrie-Allanore
- Dermatology; AP-HP, Henri Mondor hospital; Créteil France
- Referral center for toxic bullous diseases; Créteil France
| | - N. Ortonne
- Department of Pathology; AP-HP, Henri Mondor hospital; Créteil France
| | - J. Gueudry
- Referral center for toxic bullous diseases; Créteil France
- Ophtalmology; Charles Nicolle hospital; Rouen France
| | | | - M. Muraine
- Referral center for toxic bullous diseases; Créteil France
- Ophtalmology; Charles Nicolle hospital; Rouen France
| | - E. Bequignon
- Otorhinolaryngology and Facial Cervical Surgery; Intercommunal Hospital; Intercommunal hospital; Créteil France
| | - C. Gagnière
- Gastro-enterology; AP-HP, Henri-Mondor hospital; Créteil France
| | - F. Schlemmer
- Pneumology; AP-HP, Henri Mondor hospital; Créteil France
| | - P. Wolkenstein
- Dermatology; AP-HP, Henri Mondor hospital; Créteil France
- EA 7379 EpiDermE (Epidemiologie en Dermatologie et Evaluation des Thérapeutiques); Université Paris-Est Creteil Val de Marne (UPEC); Creteil France
- Referral center for toxic bullous diseases; Créteil France
| | - O. Chosidow
- Dermatology; AP-HP, Henri Mondor hospital; Créteil France
- EA 7379 EpiDermE (Epidemiologie en Dermatologie et Evaluation des Thérapeutiques); Université Paris-Est Creteil Val de Marne (UPEC); Creteil France
- Referral center for toxic bullous diseases; Créteil France
- INSERM CIC 1430; Créteil France
| |
Collapse
|
7
|
Gottlieb J, Ingen-Housz-Oro S, Alexandre M, Grootenboer-Mignot S, Aucouturier F, Sbidian E, Tancrede E, Schneider P, Regnier E, Picard-Dahan C, Begon E, Pauwels C, Cury K, Hüe S, Bernardeschi C, Ortonne N, Caux F, Wolkenstein P, Chosidow O, Prost-Squarcioni C. Idiopathic linear IgA bullous dermatosis: prognostic factors based on a case series of 72 adults. Br J Dermatol 2017; 177:212-222. [PMID: 27995619 DOI: 10.1111/bjd.15244] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/12/2016] [Indexed: 11/27/2022]
Abstract
BACKGROUND Linear IgA bullous dermatosis (LABD) is a clinically and immunologically heterogeneous, subepidermal, autoimmune bullous disease (AIBD), for which the long-term evolution is poorly described. OBJECTIVES To investigate the clinical and immunological characteristics, follow-up and prognostic factors of adult idiopathic LABD. METHODS This retrospective study, conducted in our AIBD referral centre, included adults, diagnosed between 1995 and 2012, with idiopathic LABD, defined as pure or predominant IgA deposits by direct immunofluorescence. Clinical, histological and immunological findings were collected from charts. Standard histology was systematically reviewed, and indirect immunofluorescence (IIF) on salt-split skin (SSS) and immunoblots (IBs) on amniotic membrane extracts using anti-IgA secondary antibodies were performed, when biopsies and sera obtained at diagnosis were available. Prognostic factors for complete remission (CR) were identified using univariate and multivariate analyses. RESULTS Of the 72 patients included (median age 54 years), 60% had mucous membrane (MM) involvement. IgA IIF on SSS was positive for 21 of 35 patients tested; 15 had epidermal and dermal labellings. Immunoelectron microscopy performed on the biopsies of 31 patients labelled lamina lucida (LL) (26%), lamina densa (23%), anchoring-fibril zone (AFz) (19%) and LL+AFz (23%). Of the 34 IgA IBs, 22 were positive, mostly for LAD-1/LABD97 (44%) and full-length BP180 (33%). The median follow-up was 39 months. Overall, 24 patients (36%) achieved sustained CR, 19 (29%) relapsed and 35% had chronic disease. CR was significantly associated with age > 70 years or no MM involvement. No prognostic immunological factor was identified. CONCLUSIONS Patients with LABD who are < 70 years old and have MM involvement are at risk for chronic evolution.
Collapse
Affiliation(s)
- J Gottlieb
- Dermatology Department, APHP, Henri-Mondor Hospital, Créteil, France.,Referral Center for Autoimmune Blistering Diseases, Île-de-France, France
| | - S Ingen-Housz-Oro
- Dermatology Department, APHP, Henri-Mondor Hospital, Créteil, France.,Referral Center for Autoimmune Blistering Diseases, Île-de-France, France.,Université Paris-Est Créteil Val de Marne, UPEC, DHU VIC, IRM, EA 7379 EpiDermE, Créteil, France
| | - M Alexandre
- Referral Center for Autoimmune Blistering Diseases, Île-de-France, France.,Dermatology Department, APHP, Avicenne Hospital, Bobigny, France
| | - S Grootenboer-Mignot
- Referral Center for Autoimmune Blistering Diseases, Île-de-France, France.,Department of Autoimmunity and Hypersensitivity, APHP, Bichat Hospital, Paris, France
| | - F Aucouturier
- Referral Center for Autoimmune Blistering Diseases, Île-de-France, France.,Immunology Department, APHP, Saint-Louis Hospital, Paris, France
| | - E Sbidian
- Dermatology Department, APHP, Henri-Mondor Hospital, Créteil, France.,Université Paris-Est Créteil Val de Marne, UPEC, DHU VIC, IRM, EA 7379 EpiDermE, Créteil, France.,Inserm, Centre d'Investigation Clinique 1430, Créteil, France
| | - E Tancrede
- Referral Center for Autoimmune Blistering Diseases, Île-de-France, France.,Dermatology Department, APHP, Saint-Louis Hospital, Paris, France
| | - P Schneider
- Referral Center for Autoimmune Blistering Diseases, Île-de-France, France.,Dermatology Department, APHP, Saint-Louis Hospital, Paris, France.,Pathology Department, APHP, Saint-Louis Hospital, Paris, France
| | - E Regnier
- Referral Center for Autoimmune Blistering Diseases, Île-de-France, France.,Dermatology Department, APHP, Tarnier Hospital, Paris, France
| | - C Picard-Dahan
- Referral Center for Autoimmune Blistering Diseases, Île-de-France, France.,Dermatology Department, APHP, Bichat Hospital, Paris, France
| | - E Begon
- Dermatology Department, René-Dubos Hospital, Pontoise, France
| | - C Pauwels
- Dermatology Department, Saint-Germain Hospital, Saint-Germain, France
| | - K Cury
- Referral Center for Autoimmune Blistering Diseases, Île-de-France, France.,Dermatology Department, APHP, Tenon Hospital, Paris, France
| | - S Hüe
- Referral Center for Autoimmune Blistering Diseases, Île-de-France, France.,Université Paris-Est Créteil Val de Marne, UPEC, DHU VIC, IRM, EA 7379 EpiDermE, Créteil, France.,Immunology Department, APHP, Henri-Mondor Hospital, Créteil, France
| | - C Bernardeschi
- Referral Center for Autoimmune Blistering Diseases, Île-de-France, France.,Pathology Department, APHP, Saint-Louis Hospital, Paris, France
| | - N Ortonne
- Referral Center for Autoimmune Blistering Diseases, Île-de-France, France.,Université Paris-Est Créteil Val de Marne, UPEC, DHU VIC, IRM, EA 7379 EpiDermE, Créteil, France.,Pathology Department, APHP, Henri-Mondor Hospital, Créteil, France
| | - F Caux
- Referral Center for Autoimmune Blistering Diseases, Île-de-France, France.,Dermatology Department, APHP, Avicenne Hospital, Bobigny, France.,Université Paris 13, Bobigny, France
| | - P Wolkenstein
- Dermatology Department, APHP, Henri-Mondor Hospital, Créteil, France.,Referral Center for Autoimmune Blistering Diseases, Île-de-France, France.,Université Paris-Est Créteil Val de Marne, UPEC, DHU VIC, IRM, EA 7379 EpiDermE, Créteil, France
| | - O Chosidow
- Dermatology Department, APHP, Henri-Mondor Hospital, Créteil, France.,Referral Center for Autoimmune Blistering Diseases, Île-de-France, France.,Université Paris-Est Créteil Val de Marne, UPEC, DHU VIC, IRM, EA 7379 EpiDermE, Créteil, France.,Inserm, Centre d'Investigation Clinique 1430, Créteil, France
| | - C Prost-Squarcioni
- Referral Center for Autoimmune Blistering Diseases, Île-de-France, France.,Dermatology Department, APHP, Avicenne Hospital, Bobigny, France.,Université Paris 13, Bobigny, France.,Pathology Department, APHP, Avicenne Hospital, Bobigny, France
| |
Collapse
|
8
|
Hirsch G, Ingen-Housz-Oro S, Fite C, Valeyrie-Allanore L, Ortonne N, Buffard V, Verlinde-Carvalho M, Marinho E, Martinet J, Grootenboer-Mignot S, Descamps V, Wolkenstein P, Joly P, Chosidow O. Rituximab, a new treatment for difficult-to-treat chronic erythema multiforme major? Five cases. J Eur Acad Dermatol Venereol 2015; 30:1140-3. [PMID: 26369288 DOI: 10.1111/jdv.13313] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2015] [Accepted: 06/24/2015] [Indexed: 12/11/2022]
Abstract
BACKGROUND Erythema multiforme major (EMM) is an inflammatory disease affecting skin and mucosae, often triggered by infection with Herpes simplex virus. Some patients have a chronic disease associated with antidesmoplakin autoantibodies, but the pathophysiology remains to be elucidated. First-line treatment is antiviral therapy. With treatment failure or in patients without herpes-triggered disease, thalidomide is effective but has neurological side-effects. Alternatives (dapsone, immunosuppressant agents) are not codified. For many patients, systemic steroids use is chronic. The immunosuppressant drug rituximab (RTX) may be effective. OBJECTIVES We report five cases of severe chronic EMM treated with rituximab (RTX). METHODS Five patients with severe chronic EMM for 9-20 years received RTX after failure or side-effects of several treatments, especially antiviral therapy and thalidomide. All had chronic use of steroids. Four patients had antidesmoplakin autoantibodies. RESULTS Four patients experienced complete or quasi-complete remission of EMM with withdrawal of steroids and one patient partial remission, for 3-11 months. Disease relapsed in all patients, and three received a second cycle of RTX with shorter duration of efficacy. Two patients received a third cycle, one without efficacy. CONCLUSION The use of RTX for many autoimmune diseases, especially pemphigus, is increasing. Chronic EMM, especially EMM associated to antidesmoplakin autoantibodies, is an inflammatory disease in which the role of B cells is not well understood. However, we report a favourable benefit of RTX treatment for months in five patients with severe disease. RTX could be a therapeutic option in severe, difficult-to-treat EMM.
Collapse
Affiliation(s)
- G Hirsch
- Department of Dermatology, Assistance Publique-Hôpitaux de Paris, Henri Mondor Hospital, Créteil, France
| | - S Ingen-Housz-Oro
- Department of Dermatology, Assistance Publique-Hôpitaux de Paris, Henri Mondor Hospital, Créteil, France.,EA EpiDermE (Epidémiologie en Dermatologie et Evaluation des Thérapeutiques), UPEC, Créteil, France.,Referral center for auto-immune and toxic blistering diseases, Paris, Créteil, France
| | - C Fite
- Referral center for auto-immune and toxic blistering diseases, Paris, Créteil, France.,Department of Dermatology, Assistance Publique-Hôpitaux de Paris, Bichat Hospital, Paris, France
| | - L Valeyrie-Allanore
- Department of Dermatology, Assistance Publique-Hôpitaux de Paris, Henri Mondor Hospital, Créteil, France.,EA EpiDermE (Epidémiologie en Dermatologie et Evaluation des Thérapeutiques), UPEC, Créteil, France.,Referral center for auto-immune and toxic blistering diseases, Paris, Créteil, France
| | - N Ortonne
- Department of Pathology, Assistance Publique-Hôpitaux de Paris, Henri Mondor Hospital, Créteil, France.,UPEC Université Paris-Est Créteil, Créteil, France
| | - V Buffard
- Department of Dermatology, Assistance Publique-Hôpitaux de Paris, Henri Mondor Hospital, Créteil, France
| | - M Verlinde-Carvalho
- Pharmacy, Assistance Publique-Hôpitaux de Paris, Henri Mondor Hospital, Créteil, France
| | - E Marinho
- Department of Pathology, Assistance Publique-Hôpitaux de Paris, Bichat Hospital, Paris, France
| | - J Martinet
- Department of Immunology, Rouen University Hospital, Rouen, France.,Normandie University, IRIB, Rouen, France.,INSERM, U905, Rouen, France
| | - S Grootenboer-Mignot
- Referral center for auto-immune and toxic blistering diseases, Paris, Créteil, France.,Department of Immunology, Assistance Publique-Hôpitaux de Paris, Bichat Hospital, Paris, France
| | - V Descamps
- Referral center for auto-immune and toxic blistering diseases, Paris, Créteil, France.,Department of Dermatology, Assistance Publique-Hôpitaux de Paris, Bichat Hospital, Paris, France
| | - P Wolkenstein
- Department of Dermatology, Assistance Publique-Hôpitaux de Paris, Henri Mondor Hospital, Créteil, France.,EA EpiDermE (Epidémiologie en Dermatologie et Evaluation des Thérapeutiques), UPEC, Créteil, France.,Referral center for auto-immune and toxic blistering diseases, Paris, Créteil, France.,UPEC Université Paris-Est Créteil, Créteil, France
| | - P Joly
- Department of Dermatology, Charles Nicolle Hospital, Rouen, France
| | - O Chosidow
- Department of Dermatology, Assistance Publique-Hôpitaux de Paris, Henri Mondor Hospital, Créteil, France.,EA EpiDermE (Epidémiologie en Dermatologie et Evaluation des Thérapeutiques), UPEC, Créteil, France.,Referral center for auto-immune and toxic blistering diseases, Paris, Créteil, France.,UPEC Université Paris-Est Créteil, Créteil, France.,INSERM CIC 1430, Créteil, France
| |
Collapse
|
9
|
Denoel A, Dieude P, Chollet-Martin S, Grootenboer-Mignot S. SAT0181 Immunogenicity of Rituximab in Patients with Rheumatoid Arthritis: A Kinetic Analysis. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.4232] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
10
|
Gottlieb J, Oro S, Alexandre M, Sbidian E, Aucouturier F, Tancrede E, Schneider P, Regnier E, Picard-Dahan C, Begon E, Pauwels C, Cury K, Bernadeschi C, Ortonne N, Grootenboer-Mignot S, Caux F, Chosidow O, Wolkenstein P, Prost-Squarcioni C. Les dermatoses à IgA linéaires (DIgAL) idiopathiques de l’adulte : 72 cas. Ann Dermatol Venereol 2014. [DOI: 10.1016/j.annder.2014.09.092] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
11
|
Ingen-Housz-Oro S, Grootenboer-Mignot S, Ortonne N, Nahon S, Horvath J, Bernardeschi C, Laffitte E, André C, Chollet-Martin S, Wolkenstein P, Chosidow O. Epidermolysis bullosa acquisita-like eruption with anticollagen VII autoantibodies induced by D-penicillamine in Wilson disease. Br J Dermatol 2014; 171:1574-6. [PMID: 24888462 DOI: 10.1111/bjd.13153] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
- S Ingen-Housz-Oro
- Department of Dermatology, AP-HP, Henri Mondor Hospital, 51 avenue du Maréchal de Lattre de Tassigny, 94000, Créteil, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Mekinian A, Bourrienne M, Carbillon L, Grootenboer-Mignot S, de Chaisemartin L, Fain O, Chollet-Martin S, Nicaise-Roland P. Syndrome des antiphospholipides obstétrical séronégatif. Rev Med Interne 2014. [DOI: 10.1016/j.revmed.2014.03.109] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
13
|
Oro S, Grootenboer-Mignot S, Ortonne N, Nahon S, Horvath J, Bernardeschi C, Laffitte E, André C, Wolkenstein P, Chosidow O. La D-pénicillamine pourrait induire une autoimmunité anti-collagène VII. Ann Dermatol Venereol 2013. [DOI: 10.1016/j.annder.2013.09.381] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
14
|
Ingen-Housz-Oro S, Hüe S, Grootenboer-Mignot S, André C. [Auto-immune bullous diseases autoantibodies (pemphigus, bullous pemphigoid): what the dermatologist must know]. Ann Dermatol Venereol 2013; 140:563-70. [PMID: 24034645 DOI: 10.1016/j.annder.2013.04.082] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2013] [Revised: 03/27/2013] [Accepted: 04/08/2013] [Indexed: 10/26/2022]
Affiliation(s)
- S Ingen-Housz-Oro
- Service de dermatologie, hôpital Henri-Mondor, CHU, AP-HP, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94000 Créteil, France.
| | | | | | | |
Collapse
|
15
|
Chollet-Martin S, Nicaise-Roland P, de Chaisemartin L, Grootenboer-Mignot S, Hayem G, Pelletier AL, Amiot A, Descamps V, Bouhnik Y, Meyer O. AB0497 Simultaneous determination of anti-infliximab antibodies and residual infliximab levels to monitor anti-TNF therapy. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2012-eular.497] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
16
|
Taillé C, Grootenboer-Mignot S, Nunes H, Carton Z, Cottin V, Israël-Biet D, Cadranel J, Wallaert B, Valeyre D, Chollet-Martin S, Crestani B. Prévalence et pronostic des anticorps antipériplakine au cours de la fibrose pulmonaire idiopathique. Rev Mal Respir 2013. [DOI: 10.1016/j.rmr.2012.10.092] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
17
|
Nicaise-Roland P, Nogueira L, Demattei C, Grootenboer-Mignot S, De Chaisemartin L, Rincheval N, Cornillet M, Dieude P, Dougados M, Cantagrel A, Meyer O, Serre G, Chollet-Martin S. Diagnostic performance of three assays for anticitrullinated protein antibodies in the very early arthritis 'ESPOIR' cohort. Ann Rheum Dis 2011. [DOI: 10.1136/ard.2010.149096.26] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
18
|
Grootenboer-Mignot S, Descamps V, Picard-Dahan C, Nicaise-Roland P, Prost-Squarcioni C, Leroux-Villet C, Champagnat C, Delaval A, Aucouturier F, Crickx B, Chollet-Martin S. Place of human amniotic membrane immunoblotting in the diagnosis of autoimmune bullous dermatoses. Br J Dermatol 2009; 162:743-50. [PMID: 19886889 DOI: 10.1111/j.1365-2133.2009.09566.x] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
BACKGROUND Fine analysis of antiskin autoantibodies can contribute to the differential diagnosis of autoimmune bullous dermatoses. OBJECTIVES To develop a high-performance immunoblotting method using human amniotic membrane as the antigen source, and to compare it with current laboratory methods. METHODS Sera from 113 patients were tested by immunoblotting (IB), rat and monkey oesophagus and salt-split skin indirect immunofluorescence (IIF), and enzyme-linked immunosorbent assay (ELISA) quantification of anti-BP180-NC16a and anti-BP230, or antidesmoglein (Dsg) 1 and 3 antibodies. There were 56 cases of bullous pemphigoid (BP), 22 cases of mucous membrane pemphigoid (MMP), eight cases of epidermolysis bullosa acquisita (EBA), two cases of bullous systemic lupus erythematosus (BSLE), 17 cases of pemphigus vulgaris (PV), and four cases each of pemphigus foliaceus (PF) and paraneoplastic pemphigus (PNP). RESULTS In BP, the three methods had similar sensitivity (84-89%) for both anti-BP180-NC16a and anti-BP230 antibody detection. In MMP, autoantibodies (mainly directed against BP180 or laminin 332 subunits) were detected in 77% of patients by IB, compared with only 9% by IIF on rat and monkey oesophagus and 36% on salt-split skin, and 14% by anti-BP180-NC16a and anti-BP230 ELISA. In patients with pemphigus, ELISA had 92% sensitivity for anti-Dsg1 and 3, but IB and rat bladder IIF were necessary to confirm PNP by revealing specific and rare patterns (antidesmoplakin I/II, antienvoplakin and antiperiplakin antibodies). IB also revealed anticollagen VII antibodies in 60% of patients with EBA and BSLE, and antibodies to BP180, BP230 and Dsg3 in a few patients who were negative using the other two techniques. CONCLUSION Amniotic membrane immunoblotting is an interesting diagnostic tool for bullous diseases, as the entire panel of autoantibodies can be detected with a single extract. This method improves the identification of complex and heterogeneous autoimmune processes in conjunction with IIF and ELISA, and is particularly useful for MMP characterization.
Collapse
Affiliation(s)
- S Grootenboer-Mignot
- Unité d'Immunologie 'Autoimmunité et Hypersensibilité', Hôpital Bichat-Claude Bernard, 46 rue H. Huchard, 75877 Paris Cedex 18, France.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Hurtado-Nedelec M, Chollet-Martin S, Nicaise-Roland P, Grootenboer-Mignot S, Ruimy R, Meyer O, Hayem G. Characterization of the immune response in the synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome. Rheumatology (Oxford) 2008; 47:1160-7. [PMID: 18559374 DOI: 10.1093/rheumatology/ken185] [Citation(s) in RCA: 102] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023] Open
Abstract
OBJECTIVE The aetiology of SAPHO (synovitis, acne, palmoplantar pustulosis, hyperostosis, osteitis) syndrome seems to involve genetic, infectious and immunological components. We examined innate and adaptive immune responses in SAPHO syndrome, as compared with PsA and RA. We also studied the effect of etanercept on immunological parameters. METHODS We studied 29 patients with SAPHO syndrome, as well as 22 patients with RA, 21 patients with PsA and 15 healthy controls. Adaptive immune responses were investigated by assaying total serum immunoglobulins and several autoantibodies. Innate immunity was studied by quantifying blood PMN functions and plasma cytokine levels. PMN responses to Propionibacterium acnes were tested ex vivo. Eight patients who received etanercept for refractory rheumatic disorders were tested before and after 28 days of treatment. RESULTS SAPHO syndrome was associated with elevated IL-8 and IL-18 plasma levels. IL-8 and TNF-alpha production by purified PMN was higher in the three patient groups than in the healthy controls, but the oxidative burst and IL-18 production were normal. No autoantibodies were detected in SAPHO patients. Induction of PMN IL-8 and TNF-alpha production by P. acnes was impaired in the SAPHO group as compared with the RA and PsA groups. After 28 days of etanercept therapy, PMN IL-8 and TNF-alpha production was down-regulated and TNF-alpha plasma levels were increased. CONCLUSIONS These results support the view that the SAPHO syndrome may be triggered by an infectious state involving P. acnes, contributing to the strong humoral and cellular pro-inflammatory responses. Etanercept modulation of PMN activation status emphasizes these new immunological findings.
Collapse
Affiliation(s)
- M Hurtado-Nedelec
- Immunology, Auto-immunity and Hypersensibility Unit, AP-HP Bichat Claude Bernard Hospital, Paris, France
| | | | | | | | | | | | | |
Collapse
|
20
|
Ouédraogo DD, Palazzo E, Nicaise-Roland P, Somogyi N, Grootenboer-Mignot S, Hayem G, Meyer O. Anti-cyclic citrullinated peptide antibodies (CCP2) in patients with psoriatic arthritis. Clin Exp Rheumatol 2007; 25:930-931. [PMID: 18173933] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
|
21
|
Grootenboer-Mignot S, Nicaise-Roland P, Delaunay C, Meyer O, Chollet-Martin S, Labarre C. Second generation anti-cyclic citrullinated peptide (anti-CCP2) antibodies can replace other anti-filaggrin antibodies and improve rheumatoid arthritis diagnosis. Scand J Rheumatol 2004; 33:218-20. [PMID: 15370715 DOI: 10.1080/03009740410005403] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
We compared the diagnostic performance of anti-cyclic citrullinated peptide antibodies detected with second-generation enzyme immunoassay (anti-CCP2) with that of IgM-rheumatoid factor (RF), anti-perinuclear factor (APF), and anti-keratin antibodies (AKA). The sensitivity of anti-CCP2 was better than that of APF and AKA: they were detected in 25% rheumatoid arthritis (RA) patients without detectable APF or AKA. Their specificity, evaluated in other inflammatory rheumatic disease, was similar to that of APF and AKA. Despite the lower specificity, IgM-RF in combination with anti-CCP2 is interesting, as they do not completely overlap. Anti-CCP2 antibody detection seems to be a good alternative to other anti-filaggrin antibodies in the diagnosis of RA.
Collapse
Affiliation(s)
- S Grootenboer-Mignot
- Laboratory of Immunology, AP-HP Bichat-Cl, Bernard Hospital, 75877 Paris, France
| | | | | | | | | | | |
Collapse
|